Emalex Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
- Conditions
- Tourette Syndrome in ChildrenTourette Syndrome in Adolescence
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04114539
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The University of Chicago Hospitals, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT04007991
- Locations
- 🇺🇸
Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Advanced Research Center Inc., Anaheim, California, United States
🇺🇸Clinical Research Center of NJ, Voorhees, New Jersey, United States
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02102698
- Locations
- 🇺🇸
University of South Florida/Rothman Center for Neuropsychiatry, Saint Petersburg, Florida, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Emory University School Of Medicine, Atlanta, Georgia, United States
Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
- Conditions
- Self-injurious BehaviorLesch-Nyhan Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01751802
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇺🇸H.J. Jinnah, Atlanta, Georgia, United States
Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam
- Conditions
- Healthy
- Interventions
- Drug: 90 mg controlled release formDrug: 180 mg controlled release form
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01408394
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01215357
- Locations
- 🇺🇸
University of Minnesota School of Medicine, Minneapolis, Minnesota, United States
🇺🇸Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States
🇺🇸Yale University, New Haven, Connecticut, United States